IPN Share Price Performance

€157.90

52.80 (50.24%)

€151.94

Fair Value

€157.90

52.80 (50.24%)

3.9% overvalued

€151.94

Fair Value

€157.90

€151.94

€117.00

€183.00

Fri, 10 Apr 26

Fair Value€151.94

Share Pricen/a

IPN Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value €151.94 3.9% overvalued

Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide

AnalystLowTarget's

Fair Value

Fair Value €117 35.0% overvalued

US And EU Controls And Pipeline Risks Will Erode Outlook

AnalystHighTarget's

Fair Value

Fair Value €183 13.7% undervalued

Global Healthcare Trends Will Expand Targeted Specialty Therapies

About IPN

Founded: 1929
Employees: 5535
CEO: David Loew
WebsiteView website: www.ipsen.com

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. Its oncology products include Somatuline for the treatment of neuroendocrine tumors; Cabometyx, a tyrosine kinase inhibitor to treat advanced tumor that affecting kidney; Onivyde, an irinotecan liposome injection for the treatment of metastatic pancreatic adenocarcinoma; Somatuline Autogel for the treatment of neuroendocrine tumors; and Ojemda, a Type II RAF kinase inhibitor of BRAF that is in phase III clinical trial for the treatment of pediatric low-grade glioma tumor. It also develops IPN01195, IPN60300, and IPN01203, which are in phase I clinical trial for the treatment of solid tumors; and IPN60340, BTN3A T cell activator that is in Phase II clinical trial for the treatment of acute myeloid leukemia. In addition, the company develops products for rare disease comprising Bylvay for the treatment of Biliary atresia; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; and Elafibranor, a peroxisome proliferator-activated receptor a/d agonist for the treatment of primary sclerosing cholangitis. Further, it develops Corabotase, a recombinant neuroinhibitory for the treatment of glabellar, forehead, and lateral canthal lines; adult upper limb spasticity; migraine; cervical dystonia; and chronic and episodic migraine diseases. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Recent IPN News & Updates

Announcement • May 28

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Ipsen announced the presentation of new late-breaking results from the ELATIVE Phase III trial and two real-world studies at the European Association for the Study of the Liver congress. Together, these data further strengthen the growing body of evidence establishing IQIRVO as the only second-line primary biliary cholangitis (PBC) treatment providing rapid and robust alkaline phosphatase (ALP) reduction with fatigue improvement (in patients with moderate-to-severe fatigue at baseline) and pruritus relief. In a post hoc analysis of the pivotal ELATIVE study, patients with moderate-to-severe fatigue at baseline experienced greater fatigue reductions with IQIRVO compared to placebo across 52 weeks. A clinically meaningful improvement in fatigue was achieved in 67% of patients on IQIRVO vs 31% on placebo (p=0.020) at Week 52, with improvements observed as early as Week 4. The benefits of IQIRVO vs placebo were observed across multiple dimensions of physical and mental fatigue, including extreme exhaustion (62% vs 31%), too tired to think clearly (57% vs 31%) and too tired to bath or shower (55% vs 25%), highlighting the breadth of improvement across several symptom domains. In a second late-breaking presentation, a U.S. real-world analysis using the Health Verity database, evaluated outcomes in patients with ALP elevated between 1-1.67 times the upper limit of normal (ULN). These data showed that improvements were observed through to month 6 in patients who were naïve to second-line treatment with 72% of patients having a =15% ALP reduction, a decline in mean ALP from 174 U/L to 131 U/L and 59% of patients achieving ALP normalization. Normalization of ALP is recognized as a key treatment goal for improved long-term prognosis and slowing disease progression in PBC. These data are the first real-world evidence establishing the benefit of IQIRVO on ALP normalization within this patient population. In a third late-breaker, interim month 3 findings from the global Phase IV ELFINITY study, conducted in routine clinical practice, showed IQIRVO delivered rapid and sustained reductions in ALP for three months, with biochemical response achieved in 55% of patients. More than half of patients with baseline moderate-to-severe fatigue experienced clinically meaningful improvements by month 3 as well as clinically important improvements in pruritus. IQIRVO demonstrated a favorable tolerability profile consistent with previous studies, with no serious or severe treatment-emergent adverse events reported. IQIRVO is an oral, once-daily, peroxisome proliferator-activated receptor (PPAR) agonist. Activation of PPARa and PPARd decreases bile toxicity and improves cholestasis by modulating bile acid synthesis, detoxification and transporters. IQIRVO is the first approved PPAR agonist with dual a and d activation, shown to have complementary anti-inflammatory, anti-cholestatic, anti-fibrotic and metabolic effects. In 2019, IQIRVO was granted Breakthrough Therapy Designation by the U.S Food and Drug Administration in adults with PBC who have an inadequate response to ursodeoxycholic acid (UDCA), the existing first-line therapy for PBC. IQIRVO was granted U.S. FDA accelerated approval in June 2024, conditional approval by the EMA in September 2024 and UK Medicines and Healthcare products Regulatory Agency (MHRA) in October 2024, for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The FDA and EMA approvals are contingent on the further verification of clinical benefit. In addition to the U.S., E.U. and UK, IQIRVO is approved in Canada, Australia, Brazil and 13 other countries and is in regulatory processes with other authorities. IQIRVO was developed by GENFIT. Ipsen licensed the exclusive worldwide rights (except China, Hong Kong, Taiwan and Macau) to elafibranor from GENFIT in 2021 and expanded the geographical scope to China, Hong Kong, Taiwan and Macau in March 2026.

Recent updates

No updates

Ipsen S.A. Stock Price

IPN Share Price Performance

IPN Community Narratives

Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide

US And EU Controls And Pipeline Risks Will Erode Outlook

Global Healthcare Trends Will Expand Targeted Specialty Therapies

US And EU Controls And Pipeline Risks Will Erode Outlook

Global Healthcare Trends Will Expand Targeted Specialty Therapies

Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide

Trending Discussion

Recently Updated Narratives

IPN: Oncology Safety Concerns And Pipeline Uncertainty Will Limit Future Share Upside

IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential

IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook

Snowflake Analysis

Ipsen S.A. Key Details

About IPN

Recent IPN News & Updates

IPN: Oncology Safety Concerns And Pipeline Uncertainty Will Limit Future Share Upside

Ipsen Unveils New IQIRVO Phase III Results and Strengthens Focus on Liver Disease at EASL 2026

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Recent updates

Ipsen S.A. Competitors

Sartorius Stedim Biotech

Eurofins Scientific

ABIVAX Société Anonyme